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Abstract 
Current methods for assembling metabolic pathways require a process of repeated trial and error 
and have a long design-build-test cycle. Further, it remains a challenge to precisely tune enzyme 
expression levels for maximizing target metabolite production. Recently it was shown that a cell-
free transcriptional-translation system (TX-TL) can be used to rapidly prototype novel complex 
biocircuits as well as metabolic pathways. TX-TL systems allow protein expression from 
multiple DNA pieces, opening up the possibility of modulating concentrations of DNA encoding 
individual pathway enzymes and testing the related effect on metabolite production. In this work, 
we demonstrate TX-TL as a platform for exploring the design space of metabolic pathways using 
a 1,4-BDO biosynthesis pathway as an example. Using TX-TL, we verified enzyme expression 
and enzyme activity and identified the conversion of 4-hydroxybutyrate to downstream 
metabolites as a limiting step of the 1,4-BDO pathway. We further tested combinations of 
various enzyme expression levels and found increasing downstream enzyme expression levels 
improved 1,4-BDO production.  
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Introduction 
Designing and testing biosynthesis pathways in vivo is a time-consuming and labor-intensive 
process. Cloning a pathway into plasmids in vivo has a one-week testing cycle [1]. For example, 
it took 150 person-years using this method to develop and implement production process of the 
anti-malaria drug artemisinin [2, 3]. On the other hand, cell-free transcription-translation (TX-
TL) systems can be utilized to reduce cloning iterations and streamline the process of verifying 
enzyme expression. The design-build-test cycle of a biological circuit using linear DNAs in TX-
TL takes less than one day [4], which can dramatically reduce research efforts. TX-TL allows 
simultaneous protein expression from multiple pieces of DNA, including linear DNA. Such 
properties can help quickly verify pathway enzyme expression and test pathway enzyme activity 
before a pathway is integrated in vivo.  
Metabolic pathways consisting of multiple parts and factors should be combined in 
precise combinations to achieve desired functions. Enzyme expression levels and enzyme 
activity affect target product yield. However, tuning enzyme expression requires engineering on 
the level of transcription, translation, and enzyme activity. Further, balancing expression of 
multiple genes in parallel remains a challenge. Currently, enzymes are overexpressed when they 
are identified to be important for improving target metabolite production. Protein overexpression 
can affect cell growth and possibly reduce metabolite production. A few groups have previously 
demonstrated the feasibility of tuning protein expression levels in vivo for improve metabolite 
productions [5-7]. This work aims to utilize TX-TL to rapidly tune pathway enzyme expression 
in vitro for improved metabolite productions.  
A 1,4-butanediol (BDO) biosynthesis pathway has been prototyped by 1) verifying 
enzyme expression and activity in TX-TL, 2) modulating enzyme expression levels in TX-TL for 
improved metabolite production, and 3) reconstructing the pathway in vivo. Overall workflow is 
shown in Figure 1. 1,4-BDO is an important commodity chemical with an estimated global 
market of 2.5 million ton by 2017[8]. Genomatica Inc. (San Diego, CA) previously has reported 
the production of 18g/L 1,4-BDO using an engineering E. coli strain [9]. Pathway enzymes 
include succinyl-CoA synthetase (sucCD), CoA-dependent succinate semialdehyde 
dehydrogenase (sucD), 4- hydroxybutyrate dehydrogenase (4-hbd), 4-hydroxybutyryl-CoA 
transferase (cat2), 4-hydroxybutyryl-CoA reductase (ald) and alcohol dehydrogenase (adh). The 
1,4-BDO pathway is shown below in Figure 2.  
 
 
Figure 1: Cell-free biomolecular breadboard for pathway design space exploration. From left to right, 
cloning gene sequence of pathway enzymes onto individual vectors and under the same promoter for 
verifying enzyme expression and activity, modulating enzyme expression levels for improved metabolite 
production in cell-free TX-TL systems, correlating enzyme expression in TX-TL to in vivo, and 
eventually optimizing pathway design in vivo. In parallel, mathematical models can be developed to 
identify key parameter for understanding pathway dynamics. 
 
 
Figure 2: 1,4-BDO biosynthesis pathway introduced to TX-TL: Enzymes for each numbered reactions 
are: 1) succinyl-CoA synthetase; 2) CoA-dependent succinate semialdehyde dehydrogenase; 3) 4-
hydroxybutyrate dehydrogenase; 4) 4-hydroxybutyryl-CoA transferase; 5) 4-hydroxybutyryl-CoA 
reductase; 6) alcohol dehydrogenase. Reaction 7 is a spontaneous reaction of 4-HB converting to gamma-
butyrolactone (GBL). Reactions 1, 2, and 3 are considered upstream reactions (abbreviated as U), and 
reactions 4, 5, and 6 are considered downstream reactions (abbreviated as D). 
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Result and Discussion 
Pathway enzymes were expressed in TX-TL reactions by adding linear DNA. Linear pieces of 
DNA were generated by amplifying regions encoding a promoter, a 5’-untranslated region 
(UTR), a coding sequence of an individual pathway enzyme, and a terminator. End products of 
TX-TL reactions were directly used for polyacrylamide gel electrophoresis with sodium dodecyl 
sulfate (SDS-PAGE) preparation, and all enzymes of the 1,4-BDO pathway showed up on the gel 
at expected sizes (as shown in Figure 3). Enzyme activity was verified by testing downstream 
enzymes and upstream enzymes separately. The downstream module consists of three enzymes 
that facilitate reactions after the synthesis of 4-hydroxybutyrate (4-HB), and the upstream 
module consists of three enzymes that facilitate the rest of the pathway reactions. Downstream 
and upstream modules are shown in Figure 2. Upstream enzymes were tested by adding 30 mM 
succinate in TX-TL reaction, while downstream enzymes were tested by adding 30 mM of a 
surrogate compound butyrate. TX-TL reactions were analyzed using GC-MS for expected 
metabolites, which was 4-HB and butanol. Both were detected: 4-HB at about 14 mM and 
butanol at about 1 mM.  
 
 
 
Figure 3: Verifying enzyme expression using SDS-PAGE gel: From left to right are negative control 
(NEG), succinyl-CoA synthetase (sucCD, two subunits α and β at 29.6 kDa and 41.4 kDa [10]), CoA-
dependent succinate semialdehyde dehydrogenase (sucD, 50.2 kDa), 4-hydroxybutyryl-CoA transferase 
(cat2, 48.0 kDa), 4-hydroxybutyryl-CoA reductase (ald-025b, 52.1 kDa), 4-hydroxybutyrate 
dehydrogenase (4-hbd, 41.3 kDa) alcohol dehydrogenase (adh, 43.1 kDa), 2-oxoglutarate decarboxylase 
(sucA, 100kDa), 4-hydroxybutyryl-CoA reductase (ald-002c, 95.3kDa), and protein ladder. 
 
Enzyme expression levels were modulated in TX-TL by varying concentrations of linear 
DNA encoding individual enzymes. Initially, combinations of different concentrations of linear 
DNA encoding upstream (U) and downstream (D) enzymes were tested. Enzyme ald-002c was 
used. Up to 1 mM of 1,4-BDO was detected from the linear DNA ratio of 4U:8D, which was 
about 30% more than 1,4-BDO resulted from the ratio of 8U:8D and 100% more than 1,4-BDO 
resulted from ratio of 4U:4D (shown in Figure 4a). Related metabolites were also measured 
(shown in Figure 4b). Most of the substrates got converted into 4-HB or γ-butyrolactone (GBL), 
and downstream reactions were suspected to be bottlenecks of the 1,4-BDO pathway.  
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Figure 4: a. 1,4-BDO produced in TX-TL reactions after 18 hours: error bars were estimated based on 
measurements from GC-MS and LC-MS. x-axis notation: “8U:8D” denotes for 8 nM of linear DNA 
encoding upstream enzymes and 8 nM of linear DNA encoding downstream enzymes. b. Related 
metabolites produced in the same TX-TL reactions as in a after 18 hours: 4HB—4-hydroxybutyrate, 
GBL-- gamma-butyrolactone , and SUC—succinate.  
 
To further explore the design space of the 1,4-BDO pathway, two different alds were 
tested: 002c and 025b. ald-002c is a bi-functional enzyme [9] which catalyzes both reaction 5 
and 6 shown in Figure 2. Figure 5a shows that TX-TL reactions added with ald-002c generally 
produced more 1,4-BDO than reactions added with ald-025b, regardless of enzyme expression 
levels. Reactions with ald-025b produced around 0.3 mM of 1,4-BDO. TX-TL reactions added 
with only ald-002c produced 1,4-BDO comparable to reactions added with both ald-002c and 
adh. Figure 5b again confirms metabolic flux accumulates as 4-HB or GBL and shows 
significant lactate accumulation. Pyruvate might be converted into lactate as part of the 
mechanism for regenerating ATP, which is important for protein synthesis [11].  
  
SUC semialdehyde 4-HB 4-HB CoA 4-HB aldehyde 1,4-BDO
SUC
SUC CoA
ATP, CoA
ADP, Pi NADH NAD
+ NADH NAD+ AcCoA Acetate NAD(P)H NAD(P)+
CoA
NADPH NADP+H+
GBL
H2O
upstream' downstream'
0&
2&
4&
6&
8&
10&
12&
14&
16&
18&
8U:8D& 4U:8D& 4U:4D&
Co
nc
en
tr
a8
on
s&(
m
M
)& 4HB'
GBL'
SUC'
0&
0.2&
0.4&
0.6&
0.8&
1&
1.2&
8U:8D& 4U:8D& 4U:4D&
BD
O
&C
on
ce
nt
ra
8o
n&
(m
M
)&
a.&
a.& b.&
1&
2& 3& 4& 5& 6&7&
  
Figure 5: a. 1,4-BDO produced in TX-TL reactions after 18 hours. x-axis notation: “002c (8nM)” denotes 
for 8 nM of linear DNA encoding upstream enzymes, 4-hydroxybutyryl-CoA transferase (cat2), and ald-
002c. “002c +012 (8nM)” denotes for 8 nM of linear DNA encoding upstream enzymes, cat2, and ald-
002c and adh-012. Error bars were estimated based on measurements from GC-MS and LC-MS. b. 
Related metabolites produced in the same TX-TL reactions as in a after 18 hours: 4HB (4-
hydroxybutyrate), GBL (γ-butyrolactone), Succ (succinate), and Lac (lactate).  
 
Data so far has indicated that downstream reactions are pathway bottlenecks. One 
possibility is that characteristics of downstream enzymes might affect metabolite production, and 
the reversibility of pathway enzymes were tested. 1,4-BDO and 4-HB were added into TX-TL 
reactions to test the reversibility of downstream enzymes. Figure 6 shows that the downstream 
enzymes do not convert significant amount of 1,4-BDO or 4-HB into respective upstream 
metabolites. However, significant amount of GBL was generated when 4-HB is added. It is 
likely that the spontaneous conversion from 4-HB to GBL is the key reaction that causes low 
conversion of 1,4-BDO.  
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Figure 6: Testing pathway reversibility. x-axis notation: “Dwn-BDO” denotes for 1,4-BDO added to TX-
TL reaction with linear DNA encoding downstream enzymes. Dwn—downstream enzymes, W—both 
downstream and upstream enzymes, and Up—upstream enzymes.  
 
Conclusion/Future Work 
Data above show that using linear DNA in TX-TL can tune pathway enzyme expression 
for improved metabolite productions. This set of experiments also demonstrates TX-TL’s ability 
to quickly test pathway reactions of interest without significant cloning or cell transformation. In 
the future, more concentration combinations of linear DNA encoding individual enzymes will be 
tested for improved metabolite production. Enzyme expression levels will be tuned using 
standardized transcription and translation initiation elements. Translational coupling 
architectures called bicistronic designs (BCDs) will help tune enzyme expression levels more 
reliably [12]. BCDs will be used for designing metabolic pathways to reflect enzyme expression 
levels that result with high metabolite production in TX-TL. Future work will also include 
reconstructing 1,4-BDO pathway in vivo using enzyme sequences designed with BCDs. 
Constructs for individual enzymes will contain a promoter, a BCD, coding sequences of 
individual enzymes, and a terminator. Individual enzyme constructs will be placed on plasmids 
with spacing to minimize crosstalk.  
 
Materials and Methods 
Cell-Free Expression Preparation and Execution 
Preparation of the cell-free TX-TL expression system was done according to protocols 
previously described by colleagues [13], resulting in extract with conditions: 8.9−9.9 mg/mL 
protein, 4.5−10.5 mM Mg-glutamate, 40−160 mM K-glutamate, 0.33−3.33 mM DTT, 1.5 mM 
each amino acid except leucine, 1.25 mM leucine, 50 mM HEPES, 1.5 mM ATP and GTP, 0.9 
mM CTP and UTP, 0.2 mg/mL tRNA, 0.26 mM CoA, 0.33 mM NAD+, 0.75 mM cAMP, 0.068 
mM folinic acid, 1 mM spermidine, 30 mM 3-PGA, 2% PEG-8000. When possible, inducers 
such as IPTG, pyruvate, and linear DNA were added to a mix of extract and buffer to ensure 
uniform distribution. TX-TL reactions were conducted in PCR tubes and kept at 29°C with 
incubation in PCR machine.  
 
Plasmid DNA and PCR Product Preparation 
PCR products were amplified using Pfu Phusion Polymerase (New England Biolabs). Plasmids 
were miniprepped using a QIAprep spin columns (Qiagen). All plasmids were processsed at 
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stationery phase. Before use in the cell-free reaction, both plasmids and PCR products underwent 
an additional PCR purification step using a DNA Clean & Concentrator column (Zymo 
Research), which removed excess salt detrimental to TX-TL, and were eluted and stored in 10 
mM Tris-Cl solution, pH 8.5 at 4°C for short-term storage and −20°C for long-term storage. 
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